• Inhalation Research Services
    • Efficacy studies/ Disease models
    • Formulation
    • PK studies
      • Aerosol characterization
      • In vivo PK studies
      • Ex vivo Isolated Perfused Lung method
      • In vitro dissolution tests – DissolvIt
      • In vitro cell permeability tests
    • Toxicology studies
    • Combination product development/ Device selection/ CMC data
  • Instruments
    • PreciseInhale®
      • Precision dosing
      • PreciseInhale® input: Inhaler
      • PreciseInhale® input: Nebulizer
      • White paper
    • DissolvIt ®
    • XposeALI ®
    • Nose-Only
    • Intratracheal
    • Technical specifications
  • Publications
  • Webinars
  • About
    • About Us
    • Our Customers
    • Our Team
    • Management
    • Board
    • Advisory Board
  • Investors / investerare
    • Bolagsanalys
    • Pressmeddelanden
    • Prenumerera
    • IPO 2017
    • Finansiering 2025
    • Finansiella rapporter
    • Kalender
    • Ägarlista
    • Bolagstämma
    • Bolagsstyrning
    • Presentationer
  • Contact
Inhalation
  • Inhalation Research Services
    • Efficacy studies/ Disease models
    • Formulation
    • PK studies
      • Aerosol characterization
      • In vivo PK studies
      • Ex vivo Isolated Perfused Lung method
      • In vitro dissolution tests – DissolvIt
      • In vitro cell permeability tests
    • Toxicology studies
    • Combination product development/ Device selection/ CMC data
  • Instruments
    • PreciseInhale®
      • Precision dosing
      • PreciseInhale® input: Inhaler
      • PreciseInhale® input: Nebulizer
      • White paper
    • DissolvIt ®
    • XposeALI ®
    • Nose-Only
    • Intratracheal
    • Technical specifications
  • Publications
  • Webinars
  • About
    • About Us
    • Our Customers
    • Our Team
    • Management
    • Board
    • Advisory Board
  • Investors / investerare
    • Bolagsanalys
    • Pressmeddelanden
    • Prenumerera
    • IPO 2017
    • Finansiering 2025
    • Finansiella rapporter
    • Kalender
    • Ägarlista
    • Bolagstämma
    • Bolagsstyrning
    • Presentationer
  • Contact
  • Bolagsanalys
  • Pressmeddelanden
  • Prenumerera
  • IPO 2017
  • Finansiering 2025
  • Finansiella rapporter
  • Kalender
  • Ägarlista
  • Bolagstämma
  • Bolagsstyrning
  • Presentationer

Inhalation Sciences’ captures interest and interaction at its latest industry webinar ‘Inhaled Biologics’

(Stockholm, Sweden, 13 December 2023) Interest and interaction was high on December 11 at ISAB’s latest industry webinar, ‘Inhaled Biologics’. Over 200 scientists registered for the event, the latest in ISAB’s highly popular series, with attendees logging in from Europe, Asia and the US. The webinar was co-hosted by experts in the formulation and drying of biologics, Ziccum AB.

On December 11 at 11AM EST ISAB held the latest in its popular series of co-hosted industry webinars. The series has become a regular fixture for many scientists working in inhaled therapeutics and drug development, offering deep dives, Case Studies and novel solutions into a range of challenges and areas.

This webinar, “Inhaled Biologics: Realization and Preclinical Testing of Dry Powder Formulations”, presented innovative methods for drying, formulating and testing liquid solution biologics as inhalable dry powders, including a Case Study presented by ISAB CSO Assoc Prof Per Gerde that included PK data from ISAB’s advanced specially configured IPL (Isolated Perfused Lung) test module.

The event’s co-host was Swedish biotech company Ziccum AB. Ziccum’s COO Xavier Turon presented how the company’s unique formation and drying technology for biologics, LaminarPace, originally invented by Per Gerde, turns delicate liquid solution biologics into thermostable dry powders highly suited to inhalation.

As ever ISAB’s Chief Commercial Officer Paolo Raffaelli, the organizer and host of the industry webinar series, introduced the event and moderated the Q&A.

CEO Manoush Masarrat: “These webinars give experts in the field the chance to discover and dive into new solutions and capabilities that can solve major challenges. They are an excellent technology showcase and a great opportunity for Business Development, networking and knowledge sharing”.

Watch the webinar HERE.

For more information about Inhalation Sciences, please contact: Manoush Masarrat, CEO E-mail: Manoush.masarrat@inhalation.se Mobile: +46 (0)73 628 9153

Press release in PDF format
Contact

Hälsovägen 7
Novum Floor 6, Elevator E
141 57 Huddinge, Sweden.
contact@inhalation.se
+46 (0) 705 625 195

Visitor entrance: Blickagången 6, Floor 6, Elevator E

Useful links
  • Inhalation Research Services
    • Efficacy studies/ Disease models
    • Formulation
    • PK studies
      • Aerosol characterization
      • In vivo PK studies
      • Ex vivo Isolated Perfused Lung method
      • In vitro dissolution tests – DissolvIt
      • In vitro cell permeability tests
    • Toxicology studies
    • Combination product development/ Device selection/ CMC data
  • Instruments
    • PreciseInhale®
      • Precision dosing
      • PreciseInhale® input: Inhaler
      • PreciseInhale® input: Nebulizer
      • White paper
    • DissolvIt ®
    • XposeALI ®
    • Nose-Only
    • Intratracheal
    • Technical specifications
  • Publications
  • Webinars
  • About
    • About Us
    • Our Customers
    • Our Team
    • Management
    • Board
    • Advisory Board
  • Investors / investerare
    • Bolagsanalys
    • Pressmeddelanden
    • Prenumerera
    • IPO 2017
    • Finansiering 2025
    • Finansiella rapporter
    • Kalender
    • Ägarlista
    • Bolagstämma
    • Bolagsstyrning
    • Presentationer
  • Contact
About Us

Inhalation Sciences develops and sells patented, highly innovative labtech equipment for inhalation research. Scientists using it can now know, with unprecedented accuracy, how particles behave in our lungs when we inhale them: whether new pollutants or life-saving drugs that power human development.

Privacy policy

Copyright © 2025 Inhalation. All rights reserved.

Design mkmedia
Contact us!
To top

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

Cookie Policy

Cookie Policy

At inhalation.se we use cookies as stated below. You can prevent the use of cookies at any time by pressing the icon down to your left, although this can influence your user experience on our website.

 

What are cookies?

Cookies are small text files that are placed on a computer by a web server and works just like an ID card. Cookies enable the website to remember important information, which makes your visit more convenient. Most websites use cookies to enhance the user experience and usability for you as a visitor. A cookie is a so-called passive file that can not spread dangerous software or viruses on your mobile device or computer. There are two types of cookies, permanent cookies and session cookies.

 

Permanent cookies

This cookie saves a file that remains on the user’s computer. The cookie is used to tailor a website to the user’s requirements, choices and interests, as well as for statistic follow-up, among other things.

 

Session cookies

While a visitor is on a website, this cookie is stored temporarily on the visitor’s computer. Session Cookies disappear when you close your web browser.

Cookies can be either first-party cookies or third-party cookies. First-party cookies are placed by the website you’re visiting while third-party cookies are placed by another part. Third-party cookies are often used by e.g. Google Analytics, Facebook and Remarketing with the purpose to understand how the website is used and to improve it, as well as to generate targeted advertising.

 

What cookies inhalation.se use and how to disable them

Read more about the cookies that are used on this website, their purpose, their lifespan and/or change the settings for them here.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

bscookie
Purpose: This cookie is a browser ID cookie set by Linked share Buttons and ad tags.
Domain: .www.linkedin.com
Lifespan: 2 years

lang
Purpose: This cookie is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
Domain: .ads.linkedin.com
Lifespan: session

bcookie
Purpose: This cookie is set by linkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
Domain: .linkedin.com
Lifespan: 2 years

lidc
Purpose: This cookie is set by LinkedIn and used for routing.
Domain: .linkedin.com
Lifespan: 1 day

UserMatchHistory
Purpose: Linkedin - Used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
Domain: .linkedin.com
Lifespan: 1 month

AnalyticsSyncHistory
Purpose: Used to store information about the time a sync took place with the lms_analytics cookie
Domain: .linkedin.com
Lifespan: 1 month

_gat
Purpose: Google Analytics, _”gat” is used in order to limit the number of inquiries which are made to inhalation.se
Domain: inhalation.se
Lifespan: Session

_ga
Purpose: Google Analytics, _”ga” This cookie is installed by Google Analytics. The cookie is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report.
Domain: inhalation.se
Lifespan: 2 years

Please enable Strictly Necessary Cookies first so that we can save your preferences!